CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the appointment of Amy Pott, Heidi L. Wagner, JD, and Mark H. N. Corrigan, MD, to its Board of Directors. These new independent directors deepen the Board’s expertise in clinical development, product commercialization, and government and payor relations as the company advances its clinical and preclinical pipeline and further develops PRISMTM, its proprietary discovery and drug development platform. They will also provide strategic guidance on the company’s ongoing preparations for the potential U.S. launch of suvodirsen for the treatment of boys with Duchenne muscular dystrophy who are amenable to exon 51 skipping.
